Clinical Trial Update: Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis [NA]

View source ↗

Summary

A ClinicalTrials.gov entry describes a study evaluating high-dose furmonertinib in combination with bevacizumab and pemetrexed for EGFR-mutant non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Furmonertinib (furmonertinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Non-small Cell Lung Cancer, Leptomeningeal Metastasis | NA | Status: RECRUITING